# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001069530-22-000013
Filing Date
2022-03-24
Accepted
2022-03-24 16:13:54
Documents
4
Period of Report
2021-12-31

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | sava-20211231xdef14a.htm | DEF 14A | 1293279
2 | GRAPHIC | sava-20211231xdef14ag001.jpg | GRAPHIC | 3888
3 | GRAPHIC | sava-20211231xdef14ag002.jpg | GRAPHIC | 678758
4 | GRAPHIC | sava-20211231xdef14ag003.jpg | GRAPHIC | 482016
| Complete submission text file | 0001069530-22-000013.txt |  | 2898655

Mailing Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731
Business Address 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 000-29959 | Film No.: 22766629
SIC: 2834 Pharmaceutical Preparations